Skip to main content
SpringerLink
Log in

Pharmakologische Therapie kardiologischer Erkrankungen im Alter

Geriatrische Perspektive

Pharmacological treatment of cardiovascular diseases in old age

Geriatic perspective

  • Themenschwerpunkt
  • Published:
Zeitschrift für Gerontologie und Geriatrie Aims and scope Submit manuscript

Zusammenfassung

Kardiovaskuläre Erkrankungen haben die höchste Prävalenz im fortgeschrittenen Lebensalter. Trotzdem sind höhere Altersgruppen in Randomized Controlled Trials (RCT) häufig unterrepräsentiert. Die Folge ist eine in vielen Fällen ungenügende Evidenz. Empfehlungen aus Leitlinien können daher nur bedingt auf diese Altersgruppe übertragen werden. Aufgrund der Komplexität und Vulnerabilität geriatrischer Patienten bedarf es häufig individueller Überlegungen in der pharmakologischen Therapie. Im vorliegenden Beitrag wird die Pharmakotherapie einiger relevanter kardiovaskulärer Erkrankungen aus der Perspektive eines geriatrischen Behandlungsansatzes diskutiert.

Abstract

Cardiovascular diseases have the highest prevalence in advanced age. Nevertheless, older age groups are frequently underrepresented in randomized controlled trials (RCT). Consequently, in many cases the evidence is often insufficient. Therefore, recommendations from guidelines can only be transferred to this age group to a limited extent. Due to the complexity and vulnerability of geriatric patients, individual considerations in pharmacological therapy are often required. In the following article, the pharmacotherapy of some relevant cardiovascular diseases is discussed from the perspective of a geriatric treatment approach.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Rottlaender D, Scherner M, Schneider T, Erdmann E (2007) Polypharmacy, compliance and non-prescription medication in patients with cardiovascular disease in Germany. Dtsch Med Wochenschr 132(4):139–144

    Article  CAS  PubMed  Google Scholar 

  2. Konrat C, Boutron I, Trinquart L, Auleley GR, Ricordeau P, Ravaud P (2012) Underrepresentation of elderly people in randomised controlled trials. The example of trials of 4 widely prescribed drugs. Plos One 7(3):e33559

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J et al (2001) Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 56(3):M146–M156

    Article  CAS  PubMed  Google Scholar 

  4. Leendertse AJ, Egberts AC, Stoker LJ, van den Bemt PM, Group HS (2008) Frequency of and risk factors for preventable medication-related hospital admissions in the Netherlands. Arch Intern Med 168(17):1890–1896

    PubMed  Google Scholar 

  5. Howard RL, Avery AJ, Slavenburg S, Royal S, Pipe G, Lucassen P et al (2007) Which drugs cause preventable admissions to hospital? A systematic review. Br J Clin Pharmacol 63(2):136–147

    Article  CAS  PubMed  Google Scholar 

  6. Laroche ML, Charmes JP, Nouaille Y, Picard N, Merle L (2007) Is inappropriate medication use a major cause of adverse drug reactions in the elderly? Br J Clin Pharmacol 63(2):177–186

    Article  PubMed  Google Scholar 

  7. Weingart C, Wirnsberger GH (2021) Clinical implications of the estimated glomerular filtration rate. Z Gerontol Geriatr 54(3):205–210

    Article  PubMed  Google Scholar 

  8. Gosch MHH (2014) Pharmakotherapie. In: Pantel S, Bollheimer, Sieber, Kruse (Hrsg) Praxishandbuch Altersmedizin. Kohlhammer, Stuttgart, S 642–650

    Google Scholar 

  9. Chudiak A, Uchmanowicz I, Mazur G (2018) Relation between cognitive impairment and treatment adherence in elderly hypertensive patients. Clin Interv Aging 13:1409–1418

    Article  PubMed  PubMed Central  Google Scholar 

  10. Antithrombotic Trialists C, Baigent C, Blackwell L, Collins R, Emberson J, Godwin J et al (2009) Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 373(9678):1849–1860

    Article  Google Scholar 

  11. Fowkes FG, Price JF, Stewart MC, Butcher I, Leng GC, Pell AC et al (2010) Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA 303(9):841–848

    Article  CAS  PubMed  Google Scholar 

  12. Bibbins-Domingo K, Force USPST (2016) Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. preventive services task force recommendation statement. Ann Intern Med 164(12):836–845

    Article  PubMed  Google Scholar 

  13. Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ et al (2019) ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American college of cardiology/American heart association task force on clinical practice guidelines. Circulation 140(11):e596–e646

    PubMed  PubMed Central  Google Scholar 

  14. Guirguis-Blake JM, Evans CV, Perdue LA, Bean SI, Senger CA (2022) Aspirin use to prevent cardiovascular disease and colorectal cancer: updated evidence report and systematic review for the US preventive services task force. JAMA 327(16):1585–1597

    Article  PubMed  Google Scholar 

  15. Muhlbauer V, Dallmeier D, Brefka S, Bollig C, Voigt-Radloff S, Denkinger M (2019) The pharmacological treatment of arterial hypertension in frail, older patients—a systematic review. Dtsch Arztebl Int 116(3):23–30

    PubMed  PubMed Central  Google Scholar 

  16. Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D et al (2008) Treatment of hypertension in patients 80 years of age or older. N Engl J Med 358(18):1887–1898

    Article  CAS  PubMed  Google Scholar 

  17. Williamson JD, Supiano MA, Applegate WB, Berlowitz DR, Campbell RC, Chertow GM et al (2016) Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged 〉/=75 years: a randomized clinical trial. JAMA 315(24):2673–2682

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Warwick J, Falaschetti E, Rockwood K, Mitnitski A, Thijs L, Beckett N et al (2015) No evidence that frailty modifies the positive impact of antihypertensive treatment in very elderly people: an investigation of the impact of frailty upon treatment effect in the HYpertension in the Very Elderly Trial (HYVET) study, a double-blind, placebo-controlled study of antihypertensives in people with hypertension aged 80 and over. BMC Med 13:78

    Article  PubMed  PubMed Central  Google Scholar 

  19. Welsh TJ, Gordon AL, Gladman JRF (2019) Treatment of hypertension in people with dementia: a multicenter prospective observational cohort study. J Am Med Dir Assoc 20(9):1111–1115

    Article  PubMed  Google Scholar 

  20. Freund TGB, Jeschke E (2016) Qualität der poststationären Arzneimittelversorgung von Patienten mit Herzinsuffizienz. In: Klauber JGM, friedirch J, Wasem J (Hrsg) Krankenhaus-Report. Schattauer, Stuttgart, S 229–246

    Google Scholar 

  21. Aronow WS, Ahn C, Kronzon I (1998) Normal left ventricular ejection fraction in older persons with congestive heart failure. Chest 113(4):867–869

    Article  CAS  PubMed  Google Scholar 

  22. Butt DA, Mamdani M, Austin PC, Tu K, Gomes T, Glazier RH (2013) The risk of falls on initiation of antihypertensive drugs in the elderly. Osteoporos Int 24(10):2649–2657

    Article  CAS  PubMed  Google Scholar 

  23. Savarese G, Uijl A, Lund LH, Anker SD, Asselbergs F, Fitchett D et al (2021) Empagliflozin in heart failure with predicted preserved versus reduced ejection fraction: data from the EMPA-REG OUTCOME trial. J Card Fail 27(8):888–895

    Article  PubMed  Google Scholar 

  24. Packer M, Butler J, Zannad F, Filippatos G, Ferreira JP, Pocock SJ et al (2021) Effect of Empagliflozin on worsening heart failure events in patients with heart failure and preserved ejection fraction: EMPEROR-preserved trial. Circulation 144(16):1284–1294

    Article  PubMed  PubMed Central  Google Scholar 

  25. Bruno N, Sinagra G, Paolillo S, Bonomi A, Corra U, Piepoli M et al (2018) Mineralocorticoid receptor antagonists for heart failure: a real-life observational study. ESC Heart Fail 5(3):267–274

    Article  PubMed  PubMed Central  Google Scholar 

  26. Flather MD, Yusuf S, Kober L, Pfeffer M, Hall A, Murray G et al (2000) Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 355(9215):1575–1581

    Article  CAS  PubMed  Google Scholar 

  27. Dulin BR, Krum H (2006) Drug therapy of chronic heart failure in the elderly: the current state of clinical-trial evidence. Curr Opin Cardiol 21(4):393–399

    Article  PubMed  Google Scholar 

  28. Gilstrap L, Zipkin RJ, Barnes JA, King A, O’Malley AJ, Gaziano TA et al (2022) Sacubitril/valsartan vs. ACEi/ARB at hospital discharge and 5‑year survival in older patients with heart failure with reduced ejection fraction: a decision analysis approach. Am Heart J 250:23–28. https://doi.org/10.1016/j.ahj.2022.04.007

    Article  CAS  PubMed  Google Scholar 

  29. Veenis JF, Brunner-La RHP, Linssen GC, Geerlings PR, Van Gent MW, Aksoy I et al (2019) Age differences in contemporary treatment of patients with chronic heart failure and reduced ejection fraction. Eur J Prev Cardiol 26(13):1399–1407

    Article  PubMed  PubMed Central  Google Scholar 

  30. Komajda M, Schope J, Wagenpfeil S, Tavazzi L, Bohm M, Ponikowski P et al (2019) Physicians’ guideline adherence is associated with long-term heart failure mortality in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry. Eur J Heart Fail 21(7):921–929

    Article  PubMed  Google Scholar 

  31. Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S (2007) Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 115(21):2689–2696

    Article  CAS  PubMed  Google Scholar 

  32. Friberg L, Rosenqvist M, Lip GY (2012) Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort study. Circulation 125(19):2298–2307

    Article  CAS  PubMed  Google Scholar 

  33. Akishita M, Suzuki S, Inoue H, Akao M, Atarashi H, Ikeda T et al (2022) Frailty and outcomes in older adults with non-valvular atrial fibrillation from the ANAFIE registry. Arch Gerontol Geriatr 101:104661

    Article  PubMed  Google Scholar 

  34. Kim D, Yang PS, Sung JH, Jang E, Yu HT, Kim TH et al (2022) Effectiveness and safety of anticoagulation therapy in frail patients with atrial fibrillation. Stroke 53(6):1873–1882. https://doi.org/10.1161/STROKEAHA.121.036757

    Article  CAS  PubMed  Google Scholar 

  35. Shah SJ, Singer DE, Fang MC, Reynolds K, Go AS, Eckman MH (2019) Net clinical benefit of oral anticoagulation among older adults with atrial fibrillation. Circ Cardiovasc Qual Outcomes 12(11):e6212

    Article  PubMed  PubMed Central  Google Scholar 

  36. Gosch M, Iglseder B, Heppner HJ (2016) Falls and dementia are not contraindications for anticoagulation in older adults with atrial fibrillation. Z Gerontol Geriatr 49(5):458–459

    Article  CAS  PubMed  Google Scholar 

  37. Bahrmann P, Harms F, Schambeck CM, Wehling M, Flohr J (2016) New oral anticoagulants for prophylaxis of stroke. Results of an expert conference on practical use in geriatric patients. Z Gerontol Geriatr 49(3):216–226

    Article  PubMed  Google Scholar 

  38. Feeney JM, Santone E, DiFiori M, Kis L, Jayaraman V, Montgomery SC (2016) Compared to warfarin, direct oral anticoagulants are associated with lower mortality in patients with blunt traumatic intracranial hemorrhage: a TQIP study. J Trauma Acute Care Surg 81(5:843–848

    Article  Google Scholar 

  39. Feeney JM, Neulander M, DiFiori M, Kis L, Shapiro DS, Jayaraman V et al (2017) Direct oral anticoagulants compared with warfarin in patients with severe blunt trauma. Injury 48(1):47–50

    Article  PubMed  Google Scholar 

  40. Larsen TB, Skjoth F, Nielsen PB, Kjaeldgaard JN, Lip GY (2016) Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ 353:i3189

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinikum Nürnberg, Medizinische Klinik 2 – Schwerpunkt Geriatrie, Paracelsus Medizinische Privatuniversität Nürnberg, Prof.-Ernst-Nathan-Str. 1, 90419, Nürnberg, Deutschland

    Markus Gosch

Authors
  1. Markus Gosch
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Markus Gosch.

Ethics declarations

Interessenkonflikt

M. Gosch gibt an, Vortrags- bzw. Beraterhonorare von Bayer, BMS, Böhringer, Daiichi Sankyo, Hexal, Novartis, Pfizer erhalten zu haben.

Für diesen Beitrag wurden vom Autor keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.

Additional information

figure qr

QR-Code scannen & Beitrag online lesen

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gosch, M. Pharmakologische Therapie kardiologischer Erkrankungen im Alter. Z Gerontol Geriat 55, 471–475 (2022). https://doi.org/10.1007/s00391-022-02084-w

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00391-022-02084-w

Schlüsselwörter

Keywords

Search

Navigation